. Author manuscript; available in PMC: 2014 Apr 28.

Published in final edited form as: Paediatr Respir Rev. 2010 Jun 16;11(3):177–184. doi: 10.1016/j.prrv.2010.05.003

Table 4.

Ongoing Studies of Pseudomonas aeruginosa Eradication

Investigators	No. Pts.	Type of study	Treatment Arms	Preliminary Results
ELITE (European)	88	Multicenter, Open-label, RCT	INH tobramycin × 28 or 56 days	~90% eradication in both groups 1 mo after end of treatment (conference presentation) —awaiting publication
Ratjen et al⁵³		Primary endpoint: median time to recurrence of Pa
EPIC (US)	306	Multicenter, RCT	INH tobramycin × 28 days + PO ciprofloxacin × 14 days	Preliminary results show all approaches are effective; the addition of ciprofloxacin does not appear to add any benefit (conference presentation)—awaiting publication
Treggiari et al⁵⁴		Cycled therapy based on first Pa+ culture versus culture-based therapy after initial treatment	OR PO placebo × 14 days
Belgian Study	50, 32 analyzed thus far	Single centre, RCT	INH tobramycin × 28 days	Initial Pa clearance in 82% in patients on INH tobramycin, 93% on colisitin+ciprofloxacin; 41% on INH tobramycin and 46% on colistin+ciprofloxacin remained Pa- at 6 months
Proesmans et al⁵⁵		Comparison of two antibiotic regimens in patients with new Pa+ cultures	OR INH colisitin+PO ciprofloxacin × 3 months
Australasian BAL	168 infants	Multicenter, Prospective, RCT	IV tobramycin +timentin or ceftazidime, followed by	100% eradication in all pts followed for 2 years thus far, regardless of BAL or cough suction as culture source
Wainwright et al⁵⁶		Evaluation of BAL versus non-BAL directed therapy	INH tobramycin × 2 months +PO ciprofloxacin × 1 month

RCT-randomized controlled trial; Pa-Pseudomonas aeruginosa, Pa+-Pa positive culture, Pa- -Pa negative culture, BAL-bronchoalveolar lavage, INH-inhaled, PO-oral.